Bonecker, Simone <br/><br/>
Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response.  [electronic resource] 

 -  British journal of haematology  05 2019 
 - 770-772 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.15611  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Dasatinib--therapeutic use<br/>Drug Substitution<br/>Female<br/>Fusion Proteins, bcr-abl--metabolism<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Pyrimidines--therapeutic use<br/>Survival Analysis<br/>Young Adult